Ashiya Mona 4

What Happened

• Ashiya Mona, a director of Shattuck Labs (STTK), received an award on 2026-05-29 that represents the right to purchase 81,000 shares of common stock. The Form 4 records the transaction as a derivative award (code A) with an acquisition price of $0.00; a footnote clarifies this is an option-like award rather than an immediate purchase of shares.
• This grant does not generate immediate cash proceeds and is not an exercise — it gives the holder the right to buy the shares in the future subject to vesting and other terms.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-02 (within the SEC’s 2-business-day reporting window).
• Instrument: Derivative award (option right) covering 81,000 shares; acquisition price shown as $0.00 on the filing.
• Vesting: Vests in full on the earlier of the one‑year anniversary of the grant date or immediately prior to the issuer’s next annual meeting, contingent on continued service (Footnote F1).
• Transfer obligation: The reporting person is obligated to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC; those entities will ensure benefits go to OrbiMed Private Investments IX, LP (Footnote F2). This indicates the economic/beneficial interest is intended for OrbiMed’s investment vehicle rather than a personal long‑term holding by the reporting director.
• Shares owned after transaction: The filing does not specify post-transaction personal holdings for the reporting person.

Context

• This filing documents a grant of rights to acquire shares (an award/option), not an exercise or sale. Such grants are common compensation for directors and do not necessarily signal immediate buying or selling activity in the market.
• Because the award is set to be transferred to OrbiMed’s entities, this appears to reflect an arrangement with an institutional investor rather than a standalone personal stock purchase by the director.